Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Challenges and lessons learned from a long-term postauthorisation safety study programme of rivaroxaban in Europe.
Brobert G, Ruigomez A, Schink T, Voss A, Herings R, Smits E, Swart KMA, Friberg L, Balabanova Y, Tarenz C, Suzart-Woischnik K, Soriano-Gabarró M, Vora P, Homering M, Dyszynski T, Nagel G, Amaya P, García Rodríguez LA. Brobert G, et al. Among authors: balabanova y. BMJ Open. 2024 Mar 25;14(3):e081348. doi: 10.1136/bmjopen-2023-081348. BMJ Open. 2024. PMID: 38531587 Free PMC article. Review.
Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK.
García Rodríguez LA, Martín-Pérez M, Vora P, Roberts L, Balabanova Y, Brobert G, Fatoba S, Suzart-Woischnik K, Schaefer B, Ruigomez A. García Rodríguez LA, et al. Among authors: balabanova y. BMJ Open. 2019 Sep 20;9(9):e031341. doi: 10.1136/bmjopen-2019-031341. BMJ Open. 2019. PMID: 31542760 Free PMC article.
Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UK.
Ruigómez A, Vora P, Balabanova Y, Brobert G, Roberts L, Fatoba S, Fernandez O, García Rodríguez LA. Ruigómez A, et al. Among authors: balabanova y. BMJ Open. 2019 Oct 18;9(10):e031342. doi: 10.1136/bmjopen-2019-031342. BMJ Open. 2019. PMID: 31630107 Free PMC article.
Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice.
García-Rodríguez LA, Wallander MA, Friberg L, Ruigomez A, Schink T, Bezemer I, Herings R, Shakir S, Evans A, Davies M, Suzart-Woischnik K, Vora P, Balabanova Y, Soriano-Gabarró M, Brobert G. García-Rodríguez LA, et al. Among authors: balabanova y. Expert Opin Drug Saf. 2020 Nov;19(11):1513-1520. doi: 10.1080/14740338.2020.1798928. Epub 2020 Aug 4. Expert Opin Drug Saf. 2020. PMID: 32700977
Safety and effectiveness of rivaroxaban for prevention of stroke in patients with nonvalvular atrial fibrillation: analysis of routine clinical data from four countries.
García Rodríguez LA, Ruigómez A, Schink T, Voss A, Smits E, Swart KMA, Balabanova Y, Suzart-Woischnik K, Brobert G, Herings RMC. García Rodríguez LA, et al. Among authors: balabanova y. Expert Opin Drug Saf. 2023 Jan-Jun;22(6):493-500. doi: 10.1080/14740338.2023.2181334. Epub 2023 Feb 22. Expert Opin Drug Saf. 2023. PMID: 36795067
68 results